This document provides information about Tests For Life's COVID-19 IgM/IgG Rapid Antibody Test. The test is a point-of-care test that can detect both IgM and IgG antibodies in 10-15 minutes using a small blood sample without any instrumentation. It has a combined sensitivity of 100% and specificity of 98.75%. The document describes the test's applications, protocols, validation studies, packaging, and contact information for the company.
Detecting neutralization antibodies to covid 19Melvin Alex
A robust serological test to detect neutralizing antibodies to SARS Cov-2 is needed to determine not only the infection rate, herd immunity, and predicted humoral protection, but also vaccine efficacy during clinical trials after large-scale vaccination.
Re-purposing ILRI labs to support national COVID-19 testing in KenyaILRI
Poster prepared by Edward Okoth and Samuel Oyola for the Global Agenda for Sustainable Livestock Africa 1 regional online meeting, 2-3 September 2020. Nairobi, Kenya: ILRI.
The COVID-19 pandemic is driving the need for rapid development of effective vaccines and therapies. Developing an effective vaccine requires an understanding of the adaptive immune response to SARS-CoV-2. An assay to measure circulating antibodies, specifically neutralizing antibodies (NAbs) that disrupt receptor-binding domain (RBD) and angiotensin-converting enzyme 2 (ACE2) binding to prevent SARS-COV-2 cell entry is an important research tool.
ImmunoRank is a high-throughput surrogate assay that semi-quantitative detects and ranks circulating SARS-CoV-2 neutralizing antibodies of all Ig classes (total antibody) in human plasma or serum. Highly correlated to FRNT or PRNT live virus tests, but is less laborious, takes only 80 minutes to complete, and does not require a BSL3 laboratory.
Diagnosis of tuberculosis by direct demonstration of the pathogen or by indirect demonstration of cell mediated immunity through activation of CD 4 and / or CD 8 T lymphocytes.
Detecting neutralization antibodies to covid 19Melvin Alex
A robust serological test to detect neutralizing antibodies to SARS Cov-2 is needed to determine not only the infection rate, herd immunity, and predicted humoral protection, but also vaccine efficacy during clinical trials after large-scale vaccination.
Re-purposing ILRI labs to support national COVID-19 testing in KenyaILRI
Poster prepared by Edward Okoth and Samuel Oyola for the Global Agenda for Sustainable Livestock Africa 1 regional online meeting, 2-3 September 2020. Nairobi, Kenya: ILRI.
The COVID-19 pandemic is driving the need for rapid development of effective vaccines and therapies. Developing an effective vaccine requires an understanding of the adaptive immune response to SARS-CoV-2. An assay to measure circulating antibodies, specifically neutralizing antibodies (NAbs) that disrupt receptor-binding domain (RBD) and angiotensin-converting enzyme 2 (ACE2) binding to prevent SARS-COV-2 cell entry is an important research tool.
ImmunoRank is a high-throughput surrogate assay that semi-quantitative detects and ranks circulating SARS-CoV-2 neutralizing antibodies of all Ig classes (total antibody) in human plasma or serum. Highly correlated to FRNT or PRNT live virus tests, but is less laborious, takes only 80 minutes to complete, and does not require a BSL3 laboratory.
Diagnosis of tuberculosis by direct demonstration of the pathogen or by indirect demonstration of cell mediated immunity through activation of CD 4 and / or CD 8 T lymphocytes.
Lyme disease is caused by bacterium Borrelia burgdorferi. It is transmitted to humans through the bite of infected black-legged ticks. Typical symptoms include fever, headache, fatigue, and a characteristic skin rash called erythema migrans.
The Borrelia IgM ELISA kit is an indirect enzyme immunoassay for the qualitative or quantitative determination of Borrelia IgM antibodies in human serum, plasma, and CSF samples.
RT PCR is too slow for effective control of spread of cov 2 infection, rapid antigen test by giving results in less than 30 minutes can help identify infected persons leading to quick isolation.Lack of sensitivity can be compensated by repeating RAT after a day or so.
Ab find, an antibody test after covid 19 vaccination by meril lifeYashChopra43
Meril Life has created ABFind, India's first post-covid-19 vaccine antibody test kit. Here's where you can learn about home testing for fast neutralising antibodies.
Lyme disease is caused by bacterium Borrelia burgdorferi. It is transmitted to humans through the bite of infected black-legged ticks. Typical symptoms include fever, headache, fatigue, and a characteristic skin rash called erythema migrans.
The Borrelia IgM ELISA kit is an indirect enzyme immunoassay for the qualitative or quantitative determination of Borrelia IgM antibodies in human serum, plasma, and CSF samples.
RT PCR is too slow for effective control of spread of cov 2 infection, rapid antigen test by giving results in less than 30 minutes can help identify infected persons leading to quick isolation.Lack of sensitivity can be compensated by repeating RAT after a day or so.
Ab find, an antibody test after covid 19 vaccination by meril lifeYashChopra43
Meril Life has created ABFind, India's first post-covid-19 vaccine antibody test kit. Here's where you can learn about home testing for fast neutralising antibodies.
User Menual How To USE Covid-19 Antibody Tests By Healgen HK HuZef
The COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) is
a lateral flow immunoassay intended for the qualitative detection and differentiation
of IgM and IgG antibodies to SARS-CoV-2 in human venous whole blood, plasma
from anticoagulated blood (Li+ heparin, K2EDTA and sodium citrate), or
serum. The COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma)
is intended for use as an aid in identifying individuals with an adaptive immune
response to SARS-CoV-2, indicating recent or prior infection. At this time, it is
unknown for how long antibodies persist following infection and if the presence of
antibodies confers protective immunity. The COVID-19 IgG/IgM Rapid Test
Cassette (Whole Blood/Serum/Plasma) should not be used to diagnose acute
SARS-CoV-2 infection. Testing is limited to laboratories certified under the Clinical
Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C 263a, to perform
moderate or high complexity tests.
Results are for the detection of SARS CoV-2 antibodies. IgM and IgG antibodies to
SARS-CoV-2 are generally detectable in blood several days after initial infection,
although the duration of time antibodies are present post-infection is not well
characterized. Individuals may have detectable virus present for several weeks
following seroconversion.
Laboratories within the United States and its territories are required to report all
positive results to the appropriate public health authorities.
The sensitivity of COVID-19 IgG/IgM Rapid Test Cassette (Whole
Blood/Serum/Plasma) early after infection in unknown. Negative results do not
preclude acute SARS-CoV-2 infection. If acute infection is suspected, direct testing
for SARS-CoV-2 is necessary.
False positive results for COVID-19 IgG/IgM Rapid Test Cassette (Whole
Blood/Serum/Plasma) may occur due to cross-reactivity from pre-existing
antibodies or other possible causes. Due to the risk of false positive results,
confirmation of positive results should be considered using second, different IgG or
IgM assay.
The COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) is only
for use under the Food and Drug Administration’s Emergency Use Authorization.
Accuracy report of Healgen IgG/IgM Rapid Test kits AntibodyHK HuZef
1. Accuracy
1.1 Purpose
To evaluate the equivalence of COVID-19 IgG/IgM Rapid Test result and clinical diagnosis.
1.2 Method
By testing clinical samples with known results, to evaluate the accuracy of COVID-19 IgG/IgM
Rapid Test (Whole blood/Serum/Plasma).
1.3 Material
COVID-19 IgG/IgM Rapid Test Cassette (Whole blood/Serum/Plasma)
Cassette Lot1: 2002155,Lot2:2002156,Lot3:2002157
Clinical samples
1.4 Test Procedure
1) Prepare specimens: tests were taken to clinical partner to evaluate, totally 113 specimens.
2) Perform the test according to the test procedure in the package insert
1.5 Result
1) IgM
Rapid diagnostic test for covid 19 may take around 10-20 minutes and are relatively simple to perform and interpret and therefore require limited test operator training. These slides illustrate the general concept of rapid test especially testing IgG and IgM antibodies against SARS-CoV-2 antigen .
HandleCFUS Series1000and all human blood products as though capable of transmitting infectious agents. -This product has not been FDA cleared or approved; -This product has been authorized by FDA under a EUA for use by laboratories certified under CLIA, that meet requirements to perform moderate or high complexity tests; -This product is only authorized for the duration of the declaration that circumstances
exist just if ying the authorization of emergency use of in vitro diagnostics for the detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1) unless the authorization is terminated or revoked sooner.
To study Prevalence, Pre-disposing factors and Prevention of the following MDRO’s – Klebsiella pneumoniae Carbapenemase Producer, Methicillin Resistant Staphylococcus aureus, Multi Drug Resistant Acinetobacter baumannii, Pseudomonas aeruginosa and Escherichia coli.
The first section of Part III will cover the most immediate healthcare response - which is to test and diagnose patients for COVID-19, to get a clear picture on the extent of the spread of infection. It also covers the current technologies used in diagnostics: RT-PCR, LAMP, Lateral Flow and ELISA. It would also highlight key companies and comparison of the technologies involved.
Accelerating COVID-19 Therapies: How a streamlined biosafety strategy can get...MilliporeSigma
Access the interactive recording: https://bit.ly/2xB2eRs
Abstract:
Vaccine and other biologic developers have long relied on traditional, growth-based methods for the detection of adventitious agents in a biosafety testing package. However, at a time where speed is of the essence, relying on testing methods that take many weeks is a real concern. Fortunately, alternative rapid detection methods can shorten timelines significantly — especially for Phase I testing. Here we will take you through these rapid alternatives and outline a testing strategy that can bring your therapy to the clinic faster.
Similar to Venture Diagnostic Test offers Medomices COVID-19 -IgM/ IgG Rapid Anti-Body Test (20)
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
The Importance of Community Nursing Care.pdfAD Healthcare
NDIS and Community 24/7 Nursing Care is a specific type of support that may be provided under the NDIS for individuals with complex medical needs who require ongoing nursing care in a community setting, such as their home or a supported accommodation facility.
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
Navigating Women's Health: Understanding Prenatal Care and Beyond
Venture Diagnostic Test offers Medomices COVID-19 -IgM/ IgG Rapid Anti-Body Test
1. T EST S FOR LIFE
T EST S FOR LIFE
COVID-19 IgM/IgG
Rapid Antibody Test
2. T EST S FOR LIFE
TESTS FOR LIFE
1. Certifications
2. Product Information & Advantages
3. Competitive Product Analysis
4. Overall Protocol
5. Requirements
6. Packaging
7. Summary & Contact
Content
6. T EST S FOR LIFE
Product Information
& Advantages
6
7. T EST S FOR LIFE
COVID-19 Antibody
IgM-IgG Combined Antibody Rapid Test
• Packing size: 20 tests/kit
• Specimen type: human serum, plasma, whole blood
sample (capillary or venous)
• Instrumentation: not required
• Detection time: 10-15 minutes
• Storage: Room temperature (2-30°C)
• Shelf Life:12 months
7
8. T EST S FOR LIFE
SARS-COV-2 Serological Diagnostic Test
• Serological tests are to identify antibodies
(IgM, IgG) to SARS-Cov-2 from clinical
specimen.
• Typically, IgM antibodies appear within the
first few days of the onset of symptoms and
lasts for about one month. Detection of IgM
indicates recent exposure to infection.
• IgG antibodies appear one week after the
onset of symptoms and last longer. Detection
of IgG indicates virus exposure some time
ago.
MRM (24 Jan 2019)
8
9. T EST S FOR LIFE
Test Design and Principle
9
(1) Colloidal gold-labeled recombinant novel coronavirus antigen and quality control antibody
colloidal gold marker are sprayed on conjugation pads
(2) Test line M is fixed with monoclonal anti-human IgM antibody for detecting the novel
coronavirus IgM antibody. Test line G is fixed with monoclonal anti-human IgG antibody
for detecting the novel coronavirus IgG antibody. The quality control antibody is fixed on
the C line.
10. T EST S FOR LIFE
COVID-19 Antibody
IgM-IgG Combined Antibody Rapid Test
• Our CE approved; rapid, point-of-care antibody detection test is one of
the world’s most sensitive tests for COVID-19.
• Detects both early (IgM) and late (IgG) marker antibodies in human finger
prick capillary blood, venous whole blood, serum, and plasma.
• Antibody tests have important public health and clinical uses for monitoring
and responding to the COVID-19 pandemic. It can be used for many
applications in Public Health Surveillance and patients’ health care.
10
11. T EST S FOR LIFE
COVID-19 Antibody Applications:
Antibody testing for COVID-19 has many applications. Antibody testing
determines whether you had COVID-19 in the past and now have antibodies
against the virus. A test to diagnose COVID-19 determines if you currently have
the disease.
• Antibody tests are a great tool to track infection and provide infection time course information.
• Antibody tests are needed before medical procedure done in a hospital or clinic to verify
medical procedure related to COVID-19 infections.
• Antibody tests can be used for screening COVID-19 infection recovered plasma donation and
help treat others who have severe cases of COVID-19.
• Antibody tests can be used as a diagnostic tool to measure how effective your antibodies are in
blocking the virus to help protect you from another COVID-19 infection.
11
12. T EST S FOR LIFE
COVID-19 Antibody
IgM-IgG Combined Antibody Rapid Test
12
Combined Sensitivity of 100 %
Combined Specificity of 98.75 %
One of the World’s Most Sensitive Test
13. T EST S FOR LIFE
Clinical Agreement Validation Study
IgM-IgG Combined Antibody Rapid Test
• Tests were validated against a panel of previously frozen
samples consisting of 26 SARS-CoV-2 antibody positive (both
IgM and IgG) and 80 antibody negative plasma samples.
• The antibody positive samples were collected from clinically-
confirmed COVID-19 infected patients and the presence of
anti-SARS-Cov-2 antibodies were confirmed with a
chemiluminescent IgM and IgG assay (magnetic particles).
13
14. T EST S FOR LIFE
Clinical Agreement
Validation Study Results
• Within the 26 positive samples, 22
samples tested positive for both
IgM and IgG antibodies by
BioMedomics COVID-19 IgM-IgG
Rapid Test, 4 samples tested
positive for only IgG.
• All 80 negative specimens were
collected from healthy donors and
confirmed SARS-CoV-2 antibody
negative with both the COVID-19
IgM-IgG Rapid Test and the
chemiluminescent IgM and IgG
assay.
14
15. T EST S FOR LIFE
Clinical Agreement
Validation Study Results
• The BioMedomics COVID-19 IgM-
IgG Rapid Test displayed a
combined sensitivity of 100%
(95% CI:86.77%-100%)
• The BioMedomics COVID-19 IgM-
IgG Rapid Test also displayed a
combined specificity of 98.75%
(95% CI:93.23%-99.97%)
15
16. T EST S FOR LIFE
Competitive
Product Analysis
16
17. T EST S FOR LIFE
COVID-19 Antibody
Comparison with Molecular Test
17
Serological tests such as BioMedomics’ COVID-19 IgM/IgG-
Rapid Test allows fast screening and confirmation of infection at
scale when used in conjunction with molecular tests.
19. T EST S FOR LIFE
COVID-19 Antibody
Sample Collection
19
Sample Type Method Storage
Serum Capillary or venous
Short term: 2-8°C for 5 days
Long term: store at -20°C & avoid
repeated freeze/thaw cycles
Plasma Capillary or venous
Short term: 2-8°C for 5 days
Long term: store at -20°C & avoid
repeated freeze/thaw cycles
Whole blood Capillary or venous 2-8°C for 5 days
20. T EST S FOR LIFE
COVID-19 Antibody
Instructions
20
21. T EST S FOR LIFE
COVID-19 Antibody
Instructions for Vein Blood Test
21
1. Collect blood/serum/plasma sample.
2. Add blood/serum/plasma sample to sample well.
3. Place 2 drops of buffer in sample well.
4. Read results after 10 minutes and no more than 15 minutes.
22. T EST S FOR LIFE
COVID-19 Antibody
Results
22
A total of three detection lines are possible, with the control
(C) line appearing when sample has been flowed through the
cassette.
1 | Negative Result: If only the quality control line (C)
appears and the detection lines G and M are not visible, then
no novel coronavirus antibody has been detected and the
result is negative.
2 | Positive Result, M only: If both the quality control line (C)
and the detection line M appears, then the novel coronavirus
IgM antibody has been detected and the result is positive for
the IgM antibody.
3 | Positive Result, G only: If both the quality control line (C)
and the detection line G appears, then the novel coronavirus
IgG antibody has been detected and the result is positive for
the IgG antibody.
4 | Positive Result, G and M: If the quality control line (C) and
both detection lines G and M appear, then the novel
coronavirus IgG and IgM antibodies have been detected and
the result is positive for both the IgG and IgM antibodies.
23. T EST S FOR LIFE
Internal Quality Control Procedure
IgM-IgG Combined Antibody Rapid Test
• Each Test Cassette device has a built-in control.
• A red colored line in the detection window at the Control line can be considered
an internal positive procedural control.
• The Control line will appear if the test procedure has been correctly
performed.
• If the Control line does not appear, the test is invalid and a new test must be
performed.
• If the problem persists, please contact your local vendor or BioMedomics for
technical support.
23
24. T EST S FOR LIFE
External Quality Control Procedure
IgM-IgG Combined Antibody Rapid Test
• Test performance can be evaluated using the COVID-19 External Control Kit available from
BioMedomics. Follow instructions included in the kit for preparation, use, storage, and
determination of appropriate values.
• Upon confirmation of the expected results, the test is ready to use with patient specimens.
• The COVID-19 External Control Kit includes positive external control. The positive control is
formulated by spiking humanized anti-SARS-Cov-2 antibodies in negative human serum. The
positive control may be reactive to the IgM line, IgG line or both.
• The COVID-19 External Control Kit includes negative human serum as a negative external
control. The negative control will yield an affirmative result (red line) for the control (C) line only,
when the test has been performed correctly and the test device is properly functioning.
24
28. T EST S FOR LIFE
COVID-19 Antibody
Requirements
• Facility requirement: laboratory or healthcare facility
• Intended user: trained healthcare professionals
• Storage: reagent should be stored in the dark at room
temperature (2-30°C). Container should be protected from light
after being opened. Do not freeze.
28
32. T EST S FOR LIFE
Packaging Specification
32
Type of Packaging Type of Material
Outer Kit Box Cardboard
Outer Cassette Packaging Foil Pouch
Cassette Plastic
Buffer Bottle LDPE (Low Density Polyethylene)
33. T EST S FOR LIFE
Labels
33
Outer Carton Label Buffer Label Cassette Label
35. T EST S FOR LIFE
COVID-19 IgM/IgG Rapid Antibody Test
Product Summary
• Rapid Point-of-Care Antibody Test
• Detects IgG and IgM antibodies in 10-15 minutes
• Simple to use. No instrumentation required.
• Faster & more affordable than PCR
• Intuitive visual representation
• Offer real time results
• Ships worldwide
35
36. T EST S FOR LIFE
COVID-19 Antigen
SARS-CoV-2 Rapid Test
• Rapid Point-of-Care Antigen Test for Early Infection Detection
• Detects SARS-CoV-2 in less than 15 minutes
• Simple to use. No instrumentation required.
• Faster than PCR
• More Affordable than PCR
• Offer real time results
36
37. T EST S FOR LIFE
TESTS FOR LIFE
OUR PARTNERS
• We have a global network of trusted
distributors at both the regional and
national level.
• Our products are sold in 40+ countries
including Mexico, UK, France, India,
Germany, Japan, China, Chile.
• We provide products to Hospitals,
Government Agencies, NGO’s,
Clinicians, Researchers and more.
37
38. T EST S FOR LIFE
TESTS FOR LIFE
CONCLUSION
• High-Quality Manufacturing: BioMedomics
operates under an ISO-13485 certified quality
system with dual production capacity in both the
USA and China.
• Name Recognition with Established Customers:
BioMedomics has customers in over 40 countries
around the world, serving as a foundation for
current and future global sales and marketing
activities.
• Strategic Relationships with Key Opinion
Leaders: BioMedomics maintains strong
relationships with key opinion leaders around world
to offer support and understand clinical needs,
product design implementation, along with sales
and marketing strategies.
38
39. T EST S FOR LIFE
TESTS FOR LIFE
CONTACTS
Distributor Interest & General Information:
info@biomedomics.com
Quotations & Orders:
sales@biomedomics.com
Customer Service:
custserv@biomedomics.com
Technical Support:
techsupport@biomedomics.com
39